Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 CAR-T in R/R CD7+ T-cell Malignancies
NCT05290155Phase 1Completed
- Sponsor
- Shanghai General Hospital
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD7 CAR-T cells (Shanghai General Hospital) in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), peripheral T-cell lymphoma (PTCL) and 2 more, sponsored by Shanghai General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started May 2022; status: completed.
02
Drugs
anti-CD7 CAR-T cells (Shanghai General Hospital)
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT05290155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290155.